AbbVie (ABBV) Short term Debt (2012 - 2025)

AbbVie has disclosed Short term Debt across 14 years of filings, most recently posting $2.5 billion for Q4 2025.

• In Q4 2025, Short term Debt fell 63.27% year-over-year to $2.5 billion; the TTM figure through Dec 2025 stood at $2.5 billion (down 63.27% YoY), while the FY2025 annual figure was $2.5 billion, down 63.27% from the prior year.
• Short term Debt advanced to $2.5 billion in Q4 2025, from $2.0 billion in the prior quarter.
• Over the last five years, Short term Debt for ABBV reached as high as $12.6 billion in Q2 2024 and fell as low as $3.0 million in Q1 2024.
• The 5-year median for Short term Debt is $5.1 billion (2023), against an average of $5.9 billion.
• Annual changes were most pronounced in 2021 — Short term Debt surged 188866.67% — and 2022, when it sank 99.89%.
• A 5-year view of Short term Debt shows it stood at $12.5 billion in 2021, then tumbled by 66.87% to $4.1 billion in 2022, then jumped by 73.91% to $7.2 billion in 2023, then decreased by 5.38% to $6.8 billion in 2024, then slumped by 63.27% to $2.5 billion in 2025.
• According to Business Quant data, Short term Debt over the past three periods registered $2.5 billion, $2.0 billion, and $2.0 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.